Approval · Notice of Compliance 32390 · 2023
CAPRELSA: Notice of Compliance 32390
Issued December 20, 2023
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 32390
- Date
- December 20, 2023
- Company
- Sanofi Genzyme, A Division Of Sanofi-Aventis Canada IncToronto, Ontario, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Safety update to the Product Monograph
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| CAPRELSA | Not yet assigned | — |
Medicinal ingredients
- VANDETANIB 100 MG per TAB
- VANDETANIB 300 MG per TAB